POSSIBLE INVOLVEMENT OF OATP2B1 IN GASTROINTESTINAL TOXICITY INDUCED BY SN-38, THE ACTIVE METABOLITE OF ANTICANCER IRINOTECAN

被引：0
|
作者：
Fujita, Daichi [1 ]
Saito, Yoshimasa [2 ]
Nakanishi, Takeo [1 ]
Tamai, Ikumi [1 ]
机构：
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharmaceut Sci, Dept Membrane Transport & Biopharmaceut, Kanazawa, Ishikawa, Japan
[2] Natl Canc Ctr, Dept Pharm, Tokyo, Japan
来源：
DRUG METABOLISM REVIEWS | 2015年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P522
引用
收藏
页码：287 / 288
页数：2
相关论文
共 50 条
  • [41] A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients
    Denic, Kristina Zoran
    Neuhoff, Sibylle
    Reid, Joel
    Kudget, Rachel
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [42] Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives
    Mullangi, Ramesh
    Ahlawat, Preeti
    Srinivas, Nuggehally R.
    BIOMEDICAL CHROMATOGRAPHY, 2010, 24 (01) : 104 - 123
  • [43] SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4
    Deysi Viviana Tenazoa Wong
    Helder Veras Ribeiro-Filho
    Carlos Wagner Souza Wanderley
    Caio Abner Vitorino Gonçalves Leite
    Jonilson Berlink Lima
    Alexia Nathália Brígido Assef
    Aurilene Gomes Cajado
    Gabriela Loiola Ponte Batista
    Rafael Holanda González
    Karla Oliveira Silva
    Luis Philipi Carvalho Borges
    Nylane Maria Nunes Alencar
    Diego Veras Wilke
    Thiago Mattar Cunha
    Ana Carolina Migliorini Figueira
    Fernando Queiroz Cunha
    Roberto César Pereira Lima-Júnior
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 287 - 298
  • [44] An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection
    Ziqiang Zhang
    Jing Yao
    Xiaotao Wu
    Jianjun Zou
    Jiabi Zhu
    Chromatographia, 2009, 70 : 399 - 405
  • [45] Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells
    Saga, Y
    Mizukami, H
    Suzuki, M
    Kohno, T
    Urabe, M
    Ozawa, K
    Sato, I
    CLINICAL CANCER RESEARCH, 2002, 8 (05) : 1248 - 1252
  • [46] Effects of SN-38, an active metabolite of irinotecan on p53 mediated apoptosis in human hepatocellular carcinoma cells
    Takeba, Yuko
    Kumai, Toshio
    Matsumoto, Naoki
    Kobayashi, Shinichi
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 63 - 63
  • [47] EFFECT OF BEVACIZUMAB ON P-GLYCOPROTEIN ACTIVITY AND ON THE PHARMACOKINETICS OF IRINOTECAN AND ITS MAIN ACTIVE METABOLITE (SN-38) IN VIVO
    Alili, Jean-Meidi
    Noel-Hudson, Marie-Sophie
    Chu, Celine
    Abbara, Chadi
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    ANNALS OF ONCOLOGY, 2012, 23 : 81 - 81
  • [48] SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4
    Tenazoa Wong, Deysi Viviana
    Ribeiro-Filho, Helder Veras
    Souza Wanderley, Carlos Wagner
    Vitorino Goncalves Leite, Caio Abner
    Lima, Jonilson Berlink
    Brigido Assef, Alexia Nathalia
    Cajado, Aurilene Gomes
    Ponte Batista, Gabriela Loiola
    Gonzalez, Rafael Holanda
    Silva, Karla Oliveira
    Carvalho Borges, Luis Philipi
    Nunes Alencar, Nylane Maria
    Wilke, Diego Veras
    Cunha, Thiago Mattar
    Migliorini Figueira, Ana Carolina
    Cunha, Fernando Queiroz
    Pereira Lima-Junior, Roberto Cesar
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 287 - 298
  • [49] Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)
    Gagné, JF
    Montminy, V
    Belanger, P
    Journault, K
    Gaucher, G
    Guillemette, C
    MOLECULAR PHARMACOLOGY, 2002, 62 (03) : 608 - 617
  • [50] PHARMACOKINETICS OF SN2310, AN INJECTABLE EMULSION THAT INCORPORATES A NEW DERIVATIVE OF SN-38, THE ACTIVE METABOLITE OF IRINOTECAN, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Marier, J. F.
    Pheng, L.
    Trinh, M. M.
    Brunet, J. S.
    Anderson, K.
    Gisburne, S.
    Porubek, D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1127 - 1127
12345